Location: Home /  About MGI

MGI's DNBSEQ-T20*x2 Wins 2023 Globee® Awards for Medical Equipment

Release date:2023-07-10Writer:MGIViews:2367Share

SHENZHEN, China, 5 July 2023 – MGI, a company committed to being a world-leading life science innovator, is proud to announce that its DNBSEQ-T20*×2 ("T20*") gene sequencing platform has been awarded the Globee® for Medical Equipment in the 15th Annual 2023 Golden Bridge Business and Innovation Awards®.

The Golden Bridge Awards, known for organizing world-class business awards programs and business ranking lists, honors the visionaries, innovators, and leaders who have made significant contributions in various domains of business and technology. The authority carefully selects experienced judges from diverse industries and backgrounds to conduct a comprehensive evaluation of the entries, which ensures that the award can truly reflect the outstanding achievements and contributions of the winners in their respective fields. Among the other award winners are Amazon, IBM and Meta, etc., which have also been honored for their innovative business practices. This is the second time MGI has won the Golden Bridge Awards. The first time MGI received the 2022 Globee® Awards was for Advanced COVID-19 Response Efforts. MGI has landed the Golden Bridge Awards again, which symbolizes the global recognition of MGI's cutting-edge technology advancements and significant contributions.


MGI ultra-high-throughput gene sequencer T20* was launched in February 2023, which fulfills our intention of improving the efficiency of our sequencing platform for even faster and higher throughput sequencing to make sequencing-based health monitoring and disease prevention at the molecular level affordable by all. T20* successfully drops unit cost of genome sequencing to sub $100, which will become an important driving force for the expansion of the global genetic industry, accelerate the progress of the human genome understanding and medical applications, and fundamentally reshape the industry ecology. In April 2023, T20* received its first corporate order with JMDNA Biomedical Technology Co., Ltd., which empowers the company in gene-specialized application scenarios and research projects on large population cohort and Stereo-seq, in order to facilitate scientific and technological advances. In May 2023, T20* was given the BEYOND Healthcare Innovation Award, which further proves MGI's innovative technology.


"We are honored to receive this prestigious award for two consecutive years," expressed Duncan Yu, President at MGI, "The victory of Globee® Awards further strengthens our commitment to providing innovative solutions that enable scientists to advance research and improve healthcare outcomes. And we will continue to innovate and push boundaries of what is possible in this field."


MGI has always dedicated to breaking the boundary of production capacity, aiming to provide powerful sequencers with ultra-high throughput, ultra-low cost, and intelligent integration for global users. In the future, as part of its commitment to leading life science innovation, MGI will continue to work closely with global partners to promote the healthy development of the life science industry based on its unique DNBSEQ sequencing technology, ultra-high-throughput sequencing platform, and adherence to the concept of leading life science innovation.


About MGI

MGI Tech Co., Ltd. (and its subsidiaries, "MGI"), headquartered in Shenzhen, is committed to building core tools and technology to lead life science through intelligent innovation. Based on its proprietary technology, MGI focuses on research & development, production, and sales of sequencing instruments*, reagents*, and related products to support life science research, agriculture, precision medicine and healthcare. As of December 31, 2022, MGI has more than 2,800 employees, and 36% of whom are R&D personnel. Founded in 2016, MGI operates in more than 90 countries and regions, serving more than 2,000 customers. For more information, please visit the MGI website or connect on Twitter, LinkedIn or YouTube.

*Unless otherwise informed, StandardMPS and CoolMPS sequencing reagents, and sequencers for use with such reagents are not available in Germany, Spain, UK, Sweden, Italy, Czech Republic, Switzerland and Hong Kong (CoolMPS is available in Hong Kong).

  • Hotline (Global)
  • Email
  • Special Recommendations
  • *For research use only.

    Not for use in diagnostic procedures (except as specifically noted).
Copyright © 2024 All Rights Reserved MGI Tech Co., Ltd. Guangdong ICP 16117185Privacy PolicyLegal NoticesCookie Policy
Our use of cookies
We would like to use necessary cookies to improve your browsing experience and the quality of our website. We would also like to set analytics cookies and advertisement cookies that help us make improvements by measuring how you use our website. Detailed information about the use of cookies on this website and how you can control your consent can be found in our Cookie Policy and Privacy Policy.
Accept only strictly necessary cookiesAccept all cookies